Please enable JS

Our Partnerships

Partnerships

At CRISPR Therapeutics, we view strategic partnerships as a core component of our strategy, allowing us to access capabilities and resources in support of our therapeutic programs. We are interested in partnering with biopharma companies, academic centers, universities and other relevant organizations.

To date, CRISPR Therapeutics has established two broad strategic partnerships – a research collaboration with Vertex Pharmaceuticals and a joint venture with Bayer AG – to develop gene-editing-based therapeutics in specific disease areas. Additionally, we have established a number of other relationships to advance the development of therapies utilizing CRISPR/Cas9.

For inquiries, please contact us at BD@crisprtx.com.

Major Strategic Partnerships

Vertex

CRISPR Therapeutics established a four-year strategic research collaboration with Vertex Pharmaceuticals. The initial research focuses on discovering treatments to address the underlying genetic causes of cystic fibrosis and hemoglobinopathies, specifically sickle cell disease and β-thalassemia. Vertex and CRISPR will also evaluate a specified number of other genetic targets as part of the collaboration. For the hemoglobinopathy programs, Vertex and CRISPR will equally share all research and development costs and sales, with CRISPR Therapeutics leading commercialization efforts in the U.S.  As part of the agreement, CRISPR received an up-front commitment of $105 million and is eligible to receive future development, regulatory and sales milestones, and royalties on future sales.

Read more in the press release

 

CRISPR Therapeutics and Bayer formed Casebia Therapeutics to bring breakthrough therapies to patients suffering from serious conditions such as blood disorders, blindness and congenital heart disease. CRISPR brings its proprietary CRISPR/Cas9 gene-editing technology to Casebia, while Bayer brings protein engineering expertise and deep experience in the targeted disease areas. CRISPR has 50 percent ownership in Casebia, which is fueled by $300 million in research and development funding from Bayer over five years.

Read more in the press release

 

Delivery Technologies

 

CRISPR and Casebia entered into a collaboration with CureVac to develop novel Cas9 mRNA constructs with improved properties for gene editing applications, such as increased potency, decreased duration of expression, and reduced potential for immunogenicity. CRISPR Therapeutics and Casebia have obtained an exclusive license to the improved constructs for use in three of their in vivo gene-editing programs in liver diseases. CureVac will also provide mRNA manufacturing through clinical development and commercialization of the three programs. In exchange, CureVac will receive an upfront payment and research funding, and will be eligible to receive development and commercial milestones and royalties on commercialized products arising from the collaboration.

Read more in the press release

 

CRISPR Therapeutics entered into a commercial license agreement with MaxCyte. The license provides CRISPR and Casebia, the joint venture with Bayer, a non-exclusive commercial-use right to MaxCyte’s cell engineering platform to develop CRISPR/Cas9-based therapies for hemoglobin-related diseases and severe combined immunodeficiency. CRISPR’s lead ex vivo programs utilize MaxCyte’s Flow Electroporation™ Technology to deliver CRISPR/Cas9 components to hematopoietic stem cells.

Read more in the press release

 

CRISPR Therapeutics has an exclusive license agreement with the Massachusetts Institute of Technology (MIT) for a family of Lipid Nanoparticle (LNP) technologies developed in the lab of Dr. Daniel G. Anderson, a scientific founder and advisory board member of CRISPR Therapeutics.

Read more in the press release

 

CRISPR Therapeutics entered into a collaboration and license option agreement with StrideBio to develop novel AAV vectors for in vivo gene-editing applications. Under the agreement, StrideBio will use its proprietary structure-guided evolution platform to develop AAV vectors with improved properties, such as tissue specificity and reduced susceptibility to immune responses. CRISPR has the option to exclusively license AAV vectors with desired properties for its in vivo gene-editing programs.

Read more in the press release

Immuno-Oncology

CRISPR Therapeutics formed a research collaboration with Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer. The collaboration combines each company’s proprietary technologies to explore the development of novel T cell therapies.

Read more in the press release

 

MGH

CRISPR Therapeutics has a two-year research collaboration and license option agreement with Massachusetts General Hospital Cancer Center (MGHCC) to develop novel T cell therapies for cancer. Marcela V. Maus, MD, PhD, Director of the Cellular Immunotherapy Program at MGHCC and Assistant Professor of Medicine at Harvard Medical School, will lead the scientific work at MGH. The research will involve using CRISPR/Cas9 gene editing to improve upon current T cell therapies in development, ultimately addressing unmet needs in both hematologic and solid tumors.

Read more in the press release

 

MaSTherCell

CRISPR Therapeutics has partnered with MaSTherCell SA, a full-service contract development and manufacturing organization (CDMO), on the development and manufacture of allogeneic CAR-T therapies. MaSTherCell will undertake the development and cGMP manufacture of CTX101, CRISPR’s lead allogeneic CAR-T therapy targeting CD19-positive malignancies, for use in clinical studies.

Read more in the press release

 

Exploratory

University of Florida TargetALS

Target ALS Foundation awarded a two-year grant to CRISPR Therapeutics and its collaborators at the University of Florida (UF) to support preclinical discovery and validation of CRISPR/Cas9-based therapeutic approaches directed to ALS and frontotemporal dementia. CRISPR Therapeutics will collaborate with Dr. Laura Ranum and Dr. Eric Wang at UF to test CRISPR/Cas9 gene editing strategies in animal models of the disease.

Read more in the press release

 

University of Florida TargetALS

CRISPR Therapeutics has received Kyle Bryant Translational Research Award from Friedreich’s Ataxia Research Alliance (FARA), a non-profit organization that is focused on curing Friedreich’s Ataxia (FA).The grant is awarded to fund research on in vivo CRISPR/Cas9-based gene-editing approaches to treat FA, which will be performed in collaboration with Dr. Marek Napierala at University of Alabama at Birmingham. Under the terms of the grant, CRISPR Therapeutics will develop gene-editing reagents with the potential to address the underlying genetic causes of FA. Dr. Napierala and colleagues will then evaluate the reagents in humanized animal models of FA to demonstrate preclinical proof-of-concept. Upon conclusion of these studies, CRISPR Therapeutics will have the option to advance the compounds into clinical trials.